New Immune-Chemo cocktail aims to shrink inoperable lung tumors

NCT ID NCT07082179

Recruiting now Disease control Sponsor: Jiangsu Cancer Institute & Hospital Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial is testing a combination of two immune-boosting antibodies (iparomlimab and tuvonralimab) plus chemotherapy for people with stage III non-small cell lung cancer that cannot be removed by surgery. The study will enroll 33 adults who have not had prior treatment. The goal is to see if the treatment can shrink tumors enough to allow surgery or improve outcomes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: iparomlimab and tuvonralimab (immune-boosting antibodies) plus paclitaxel polymer micelles and platinum chemotherapy (cisplatin or carboplatin)
What this could lead to: If successful, this combination could shrink or control advanced lung cancer tumors, potentially allowing more patients to become candidates for surgery.
What could go wrong: This is a small, early-phase trial with only 33 participants, so results may not apply broadly. The drug combination may cause significant side effects, and it is not yet known if it improves survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NSCLC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NSCLC

Contacts and locations

Locations

Jiangsu Provincial Cancer Hospital
RECRUITING

Nanjing, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.